Association of Co-Morbidities with Prescribing Patterns and Cost Savings

Wei Yu (), Xinhua Ren, Austin Lee, Lawrence Herz, Yu-Hui Huang and Lewis Kazis

PharmacoEconomics, 2006, vol. 24, issue 12, 1233-1248

Abstract: Among the top 10% most expensive patients, olanzapine and risperidone treatments were associated with comparable cost reductions in inpatient care. The choice of agent was associated with patients’ co-morbid condition and was correlated with cost reduction in inpatient medical/surgical or psychiatric care. Copyright Adis Data Information BV 2006

Date: 2006
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.2165/00019053-200624120-00007 (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:24:y:2006:i:12:p:1233-1248

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.2165/00019053-200624120-00007

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().